cp wire

CP Wire Articles

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 ARCHES trial evaluating Xtandi (enzalutamide)... read more

Thu, 12/20/18 - 10:19 am

On 12/20/18, Relay Therapeutics announced the successful completion of a $400 million Series C financing.

Relay Therapeutics combines unprecedented computational power with leading... read more

Thu, 12/20/18 - 09:57 am

Equillium, Inc. (Nasdaq: EQ) announced on 12/19/18 that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for EQ001 for the treatment of acute graft-versus-host... read more

Wed, 12/19/18 - 10:15 am

Auron Therapeutics and Elucidata Corporation on 12/19/18 announced a scientific collaboration using Elucidata’s AI-based target discovery platform to identify and validate targets for... read more

Wed, 12/19/18 - 10:00 am

Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, announced on 12/19/18 that... read more

Wed, 12/19/18 - 09:39 am

Versant Ventures announced on 12/17/18 that it raised USD100 million for a Canadian fund called Versant Voyageurs I. Voyageurs will be deployed across five to eight startup companies with Canadian... read more

Mon, 12/17/18 - 11:02 am

Merck [NYSE:MRK] and privately held Antelliq Group announced on 12/14/18 that the companies have signed a definitive agreement under which Merck will acquire Antelliq from funds advised by BC... read more

Fri, 12/14/18 - 10:40 am

Two programs (one in the US and one in the UK) offering life science companies lab space and access to capital and advisors made announcements about lab space for seed and early stage
... read more

Fri, 12/14/18 - 10:03 am
  • The vaccine received Breakthrough Therapy designation in September, 2018
  • It received Fast Track designation in October, 2017

Pfizer Inc. (NYSE:PFE) announced today... read more

Fri, 12/14/18 - 09:10 am

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that Tremfya (guselkumab) was superior to Cosentyx (secukinumab)* in... read more

Wed, 12/12/18 - 10:46 am
  • VE800, is based on work showing in preclinical models that certain gut-dwelling bacterial strains potentiate cytotoxic CD8+ T cells and enhance infiltration into tumors
  • Bristol-Myers... read more
Mon, 12/10/18 - 10:57 pm

Biological Dynamics announced on 12/7/18 that its OmniVerita system has been selected as the winner of CONNECT’s Most Innovative New Product Award in the Life Science Products, Clinical Stage... read more

Fri, 12/7/18 - 10:36 am

Kallyope Inc., a leading biotechnology company focused on identifying therapeutic opportunities involving the gut-brain axis, today announced a $21 million expansion of its previously... read more

Wed, 12/5/18 - 02:44 pm
  • Ruling will confirm European regulatory exclusivity for Rubraca until at least 2028
  • Clovis also recently received a patent for using Rubraca in high doses to treat cancer in the US... read more
Tue, 12/4/18 - 09:13 am

Proteintech, the benchmark in antibodies since 2001, and BenchSci, a life science machine learning startup backed by Google’s AI fund, have announced a new partnership to accelerate science by... read more

Mon, 12/3/18 - 10:33 am

Aetna, a CVS Health business, and Ascension have joined the pilot project applying blockchain technology to improve data quality and reduce administrative costs associated with changes to health... read more

Mon, 12/3/18 - 10:10 am

ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, announced on 12/3/18 that it has entered a... read more

Mon, 12/3/18 - 09:55 am


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.